Patent Eligibility Restoration Act of 2025

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $1,530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Issues related to intellectual property including S. 1553, the PREVAIL Act, S.1546, the Patent Eligibility Restoration Act of 2025, and S.708, the RESTORE Patent Rights Act of 2025 Issues related to Patent Trial and Appeal Board procedures

Client expense: $1,610,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform. H.R. 1574, RESTORE Patent Rights Act of 2025. H.R. 3152, Patent Eligibility Restoration Act of 2025. H.R. 3160, PREVAIL Act. H.R. 3269, ETHIC Act. H.R. 9681, Fair Seeds for Farmers Act. S. 708, RESTORE Patent Rights Act of 2025. S. 1546, Patent Eligibility Restoration Act of 2025. S. 1553, PREVAIL Act. S. 2276, ETHIC Act. S. 5104, Fair Seeds for Farmers Act.

Client expense: $1,710,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Client expense: $3,150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the rules governing the Patent Trial and Appeals Board, including both legislative and regulatory proposals. PREVAIL Act, S. 1553 Patent Eligibility Restoration Act, S. 1546. General opposition to legislative efforts to weaken the Patent Trial & Appeal Board at the USPTO.

Client expense: Not reported · Firm income: $20,000

Government targets: SENATE

Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act

Client expense: Not reported · Firm income: $70,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, White House Office

Intellectual property and patent issues; Standard Essential Patents; Intellectual Property/Patent enforcement at the International Trade Commission; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; Export Control issues

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Software copyright and related policy issues. Software patents and related policy issues. S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S. 1546, Patent Eligibility Restoration Act. S. 1367, NO FAKES Act. S. 4098, AI Ready Data Act.

Client expense: $2,440,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Copyright Office, U.S. Trade Representative (USTR)

Met with Senators, Representatives, and legislative staff to discuss university intellectual property and technology transfer operations, and to encourage support for the PREVAIL (HR 3160, S.1553), PERA (HR 3512, S.1546), and RESTORE (HR 1578, S.704) Acts. Met with Senators, Representatives, and legislative staff to encourage support for efforts to prevent agencies from indiscriminately exercising march-in rights to invalidate university patents or licenses, or to discourage the administration from claiming a portion of patent royalties.

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patent reform legislation; Issues related to patent reform legislation and regulation, including S. 1546 - the Patent Eligibility Restoration Act of 2025.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S.1367, NO FAKES Act, Section 2, voice and visual likeness. S.1546 - Patent Eligibility Restoration Act, all provisions. S.4145/H.R.4072 - Pro Codes Act of 2026, all provisions.

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform

Client expense: $840,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

Issues related to patent rights and patent enforcement; Issues related to H.R. 3160/S. 1553 - PREVAIL Act; Issues related to H.R. 3152/S. 1546 - Patent Eligibility Restoration Act of 2025; Issues related to H.R. 1574/S. 708 - RESTORE Patent Rights Act of 2025; Issues related to Section 337; H.R. 8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027; Issues related to the NPRM on Revision to Rules of Practice Before the Patent Trial and Appeal Board.

Client expense: Not reported · Firm income: $80,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Good Government White House Conference on Small Business Act, H.R. 6855: Support action by U.S. House to advance the legislation. DME Scammer Prevention Act of 2026, H.R. 8871: Support the legislation and advancement through House Ways and Means Committee. Preventing Waste, Fraud and Abuse in TANF Act, H.R. 8872: Support the legislation and advancement through House Ways and Means Committee. Protecting Seniors and Stopping Fraudsters Act, H.R. 8883: Support the legislation and advancement through House Ways and Means Committee. Recover COVID Unemployment Fraud in Banks Act, H.R. 8873: Support the legislation and advancement through House Ways and Means Committee. Workforce Issues Valuing Employee Stock Today Act, H.R.8660: Support the legislation. Workforce Apprenticeship Growth and Education Support (WAGES) Act, H.R. 8624 and S. 4463: Support the legislation. Empowering Employer Child and Elder Care Solutions Act, H.R. 2270: Continue to support U.S. House passage of the bill. Working Families Flexibility Act, H.R. 2870: Continue to support full U.S. House passage of the bill. Tipped Employee Protection Act, H.R. 2312: Continue to support U.S. House passage of the bill. Access to Capital: INVEST Act, H.R. 3383: Continue to support U.S. Senate passage of this Housed-passed bill. Comments to Securities and Exchange Commission: Submitted comments in in support of a petition to raise the Regulation Crowdfunding offering limit to $20 million. Tax Policy Small Business Tax Cut Act, H.R. 8415: Support the legislation. Indexing Capital Gains Tax Liability to Inflation: Support legislative or administrative action to make this reform. More Homes on the Market Act, H.R. 1340, S.3332: Support the legislation. American Innovation Act, H.R. 1778, S. 4207: Support the legislation. Business Startup & Growth SAVE Local Businesses Act, H.R. 4366: Support U.S. House passage of the bill. New Opportunities for Business Ownership and Self-Sufficiency Act (NO BOSS Act), H.R. 6431: Supported U.S. House passage of the legislation and U.S. Senate introduction of the legislation. American Innovation Act, H.R. 1778, S. 4207: Support the legislation. AI and Technology Continue to voice restraint on excessive regulatory frameworks or actions that would undermine what is a critical new technology for small businesses. Comments to Federal Trade Commission: Submitted comments on the Proposed Enforcement Policy Statement Regarding Personalized Pricing, expressing concerns about the scope of the proposal the proposed frameworks misunderstanding of how dynamic and data-driven pricing tools are utilized by small businesses, and therefore how it would negatively impact their competitiveness and growth. AI Education: Continue to brief congressional staff on the benefits of AI to small businesses and startups as conveyed through SBE Council research and surveys. American Innovation and Choice Online Act (AICOA). S. 4746: Continue to oppose the legislation. Regulatory Modernization and Reform Guidance Out of Darkness (GOOD) Act (H.R. 1515): Urged Senate to advance House-passed bill. Bipartisan American Affordability and Jobs Act: Support the Senate introduced legislation. Latest Action on CTAs BOI Rule: Expressed support for the U.S. Department of the Treasury and Financial Crimes Enforcement Network (FinCEN) step in finalizing its rule ending the Beneficial Ownership Information (BOI) reporting mandate for U.S. businesses and individuals under the Corporate Transparency Act (CTA), and for taking the important additional step of deleting previously submitted information pertaining to U.S. persons. Comments to Small Business Administration: Submitted comments on the SBAs Proposed Small Business Size Standards, expressing support for modernization but a reconsideration of aspects of the methodology that could unintentionally disadvantage the very firms SBA exists to serve. Comments to Securities and Exchange Commission: Submitted comments in support of the Proposed Rule on Semiannual Reporting. NEPA Modernization: Expressed support for the Federal Communications Commissions vote to modernize its National Environmental Policy Act (NEPA) rules and streamline permitting for communications infrastructure. Packaging and Claims Knowledge Act (PACK Act), H.R. 6832: Support the legislation. Information Quality Assurance Act (H.R. 6329): Urged Senate to advance House-passed bill. ESA Amendments Act, H.R. 1897: Continue to support U.S. House passage of the bill. Prove It Act of 2025, H.R. 1163: Continue to support full U.S. House action and passage of the bill. Reducing and Eliminating Duplicative Environmental Regulations (RED Tape) Act, H.R. 6398: Supported House passage of the legislation and Senate action. Standardizing Permitting and Expediting Economic Development Act (SPEED Act), H.R. 4776: Continue to support Senate action on House-passed bill. Promoting Efficient Review for Modern Infrastructure Today (PERMIT) Act, H.R. 3898: Continue to support Senate action on House-passed bill. Repealing Big Brother Overreach Act, H.R. 425: Continue to support the legislation. Nominations Supported the nomination and confirmation of Keith Sonderling as U.S. Labor Department Secretary. Government Reform and Operations Tax Relief for Fraud Victims Act, H.R. 9500: Supported U.S. House passage of the legislation. AI Tax Integrity Act of 2026, H.R. 9501: Support full U.S. House passage of the legislation. Taxpayer Advocate Participation Act, H.R. 9498: Supported U.S. House passage of the legislation. Taxpayer Assistance and Service Act. S. 3931: Support full U.S. Senate passage of the legislation. Taxpayer Due Process Enhancement Act, H.R. 6506: Support U.S. Senate action on the House-passed bill. Taxpayer Notification and Privacy Act, H.R. 6495: Continue to support U.S. Senate action on the House-passed bill. Healthcare and Affordable Health Coverage HSAs For All Act, H.R. 7681: Continue to support the legislation. Lower Health Care Premiums for All Americans Act, H.R. 6703: Support Senate action of House-passed bill. Comments to the Centers for Medicare & Medicaid Services: Submitted comments on the proposed Medicare Program: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program rule, opposing CMSs proposed modification for initial price applicability year (IPAY) 2029 that would change how the agency identifies a qualifying single source drug under the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act (IRA). Request for Information on Common Sense Policy Options to Lower Drug Prices for Patients: Submitted comments to Senate Finance Committees (via Ranking Member Wyden) Request for Information on policy options to lower prescription drug costs. 340B Drug Program: Continue to voice concerns about this program to Congress (in terms of effects on high drug and health premium costs) and the need for reforms. Abolish the Center for Medicare and Medicaid Innovation (CMMI) Act, H.R. 8293: Support the legislation. Intellectual Property Patent Eligibility Restoration Act (PERA), S. 1546: Reiterated support for the Senate introduced bill. Trade and Global Market Access Comments to the Office of the United States Trade Representative: Submitted comments on the 301 Investigation into Germanys persistent underpayment for innovative drugs, expressing encouragement about the investigation into the countrys unfair pharmaceutical pricing and the use of available USTR tools to press Americas trading partners to lift their price controls and contribute fairly to the innovation ecosystem from which they benefit American Global Competitiveness at 250: Legislative Proposals to Secure U.S. Technology Leadership: Submitted written testimony for the record before U.S. House Committee on Energy and Commerce expressing concerns about the European Unions Corporate Sustainability Due Diligence Directive (commonly referred to as CSDDD or CS3D) and the significant implications it poses for American businesses, small businesses and entrepreneurs. USMCA Review: Expressed overall support for the USMCA as it undergoes a review process. Urged the Administration to focus on strengthening and building upon the success of USMCA, make changes where warranted - such in the area of enforcement - so as not to destabilize supply chains and markets have become increasingly important to Americas entrepreneurs and small businesses.

Client expense: $35,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)

S.3971- SBIR/STTR Reauthorization Act of 2026 H.R. 5100 - To extend the SBIR and STTR programs, and for other purposes S.1546 - Patent Eligibility Restoration Act of 2025 S.1553 - PREVAIL Act H.R.5223 - RESTORE Act of 2025 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $125,337 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).

Client expense: Not reported · Firm income: $610,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE

H.R. 5811: Restoring Americas Leadership in Innovation Act of 2025; All provisions of the bill; H.R. 5819: Balancing Incentives Act of 2025; All provisions of the bill; S. 708 / HR. 1574 RESTORE Patent Rights Act of 2025: All provisions of the bill; S. 1546 / HR. 3152 Patent Eligibility Restoration Act of 2025: All provisions of the bill; S. 1553 / HR. 3160 PREVAIL Act: All provisions of the bill.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to the the Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) (H.R. 3152) and Patent Eligibility Restoration Act (PERA) (S. 1546) patent legislation

Client expense: $340,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

AI/ ML GenAI, Digital Replicas "NO FAKES Act," S. 4591, S.1367, H.R. 2794 Patents, Patent Reform "PERA," S. 1546 Judiciary, Specialized Courts

Client expense: Not reported · Firm income: $34,875

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office

S. 708 and H.R. 1534 -- RESTORE Patent Rights Act of 2025 -- issues related to injunctions for patent infringement S. 1546 and H.R. 3152 -- Patent Eligibility Restoration Act -- related to clarifications of Section 101 of patent law S. 1553 and H.R. 3160 -- PREVAIL Act (Promoting and Respecting Economically Vital American Innovation Leadership Act -- related to reforms of the Patent Trials and Appeals Board at the US Patent and Trademark Office Teleconference with OIRA and USPTO re: Revision to Rules of Practice before the Patent Trial and Appeals Board Extension of PTO's fee-sharing authority which expired in September 2026 Restrictions in federal research grants that could lead to payments to government

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, White House Office

S.1546 Patent Eligibility Restoration Act of 2025; S.1553 PREVAIL Act; S.708 RESTORE Patent Rights Act of 2025. USPTO Proposed Rulemakings on PTAB Reform and Disclosure of Real Parties in Interest.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE

H.R. 10575/S. 5529, the Deterring Extraterritorial Foreign Exploitation of Networks Damaging Intellectual Property (DEFEND IP) Act of 2026 S. 5104/H.R. 9681, Fair Seeds for Farmers Act H.R. 10204, Legislative Branch Agencies Clarification Act H.R 10364 American Copyright Protection Act of 2026 H.R. 10026, Honoring Circuit Judge Pauline Newman Act of 2026 H.R. 10025, Preventing Abuse of Digital Replicas Act H.R. 7140, Customer Legal Ease and Relief Act (CLEAR Act) H.R. 5811, Restoring Americas Leadership in Innovation Act of 2025 S. 3517, the Visual Artists Copyright Reform Act of 2025 H.R. 6517, To modify the appointment process for the Librarian of Congress, the Comptroller General, and the Director of the Government Publishing Office, and for other purposes H.R. 6028, Legislative Branch Agencies Clarification Act S. 1546/H.R. 3152, Patent Eligibility Restoration Act (PERA) of 2025 S. 1553/ H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) S. 1833/H.R. 3539, Leadership in CET Act S. 2677/H.R. 4930, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade S. 2455, TRAIN Act S. 2276/H.R. 3269, ETHIC Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 890, A bill to amend title 35, United States Code, to prevent double patenting, and for other purposes. H.R.1109, the Litigation Transparency Act of 2025 H.R. 2675, Protecting Our Courts from Foreign Manipulation Act of 2025 S. 1367/H.R. 5794, NO FAKES H.R 791, Foreign Anti-Digital Piracy Act (FADPA) S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 1041, Affordable Prescriptions for Patients Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 6485/S. 43, Skinny Labels, Big Savings Act Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Operations

Client expense: $10,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: Not reported

Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).

Client expense: Not reported · Firm income: $110,000

Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office

Issues related to intellectual property and innovation policy oversight, including S 1546, the Patent Eligibility Restoration Act

Client expense: Not reported · Firm income: $20,000

Government targets: SENATE

H.R.8163 - To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce programs under title VII of the Public Health Service Act H.R.7961 - Physicians and the Healthcare Workforce Act S.4086 - A bill to establish protections for health care providers who raise concerns about the quality of health care services, and for other purposes S.4039 - Professional Degree Access Restoration Act H.R.7884 - To amend the Internal Revenue Code of 1986 to provide a tax credit to health care professionals that provide health care services in qualifying facilities, and for other purposes; S.3908 - SOS: Sustaining Outpatient Services Act H.R.7686 - To recognize the importance of clinical roles of locum tenens physicians, and for other purposes H.R.7520 - Efficiency Adjustment Delay Act S.3762 - Prior Authorization Relief Act H.R.7118 - Genomic Answers for Childrens Health Act H.R. 1, the One Big, Beautiful Bill Act Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs PAMA reform S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine LCD legislation HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts HR 5392, the Timely Access to Coverage Decisions Act of 2023 Remote digital telepathology HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act Gene Therapy HR 6371 - budget neutrality bill S. 1546/H.R. 3152 The Patent Eligibility Restoration Act Cures 2.1 S. 4935, Physician Fee Stabilization Act Medical Lab Personnel Shortage Relief Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 Issues relating to regulation of laboratory diagnostics CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to public health Conrad 30 Physician Workforce Optimization Act (S. 4637) H.R.9645 - Health Care Price Certainty for All Americans Act H.R. 9693 - The Patients First Act S 5180 Provider Reimbursement Stability Act S 5062 - FAIR DME Appeals Act H.R. 8500 / S. 5745 - Timely Access to Coverage Decisions Act ROOT Act HR 8890 the Enhancing CLIA Act

Client expense: $203,130 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 708/H.R. 1574, Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive Patent Rights (RESTORE) Act of 2025; S. 1546/H.R. 3152, Patent Eligibility Restoration Act of 2025; S. 1553/H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act; Issues related to the International Trade Commission (ITC); Issues related to Intellectual Property Right and Patents.

Client expense: $570,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Software copyright and related policy issues. Software patents and related policy issues. S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S. 1546, Patent Eligibility Restoration Act.

Client expense: Not reported · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE, U.S. Copyright Office

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.4145/H.R.4072 - Pro Codes Act of 2026, all provisions S. 4591 NO FAKES Act, Section 2, voice and visual likeness rights H.R. 6028, Legislative Branch Agencies Clarification Act, Perry Amendment S.1546 - Patent Eligibility Restoration Act, all provisions proposed legislation regarding 17 USC 1201 and accessibility

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to intellectual property including S. 1553, the PREVAIL Act, S.1546, the Patent Eligibility Restoration Act of 2025, and S.708, the RESTORE Patent Rights Act of 2025

Client expense: $1,180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1367/H.R.2794, NO FAKES Act of 2025, NO FAKES Act of 2026 / S.4591 Proposals for blocking foreign piracy websites S. 1546/H.R. 3152, Patent Eligibility Restoration Act of 2025 S. 1553/H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 7140, Customer Legal Ease and Relief (CLEAR) Act

Client expense: $1,396,909 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Compulsory Licensing ---28 U.S.C. 1498 - Patent and copyright cases Data Privacy ---H.R.8413: SECURE Data Act ---Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act of 2025 ---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA) ---S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act of 2025 ---Department of Commerce Patent Valuation Fee Proposal ---Patent Litigation Reform ---Patent Tax/fees ---PTAB Reform ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Intellectual Property Enforcement ---China

Client expense: $2,360,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, Treasury, Dept of

Patent Protection and IP issues generally. S. 1546, Patent Eligibility and Restoration Act (PERA) HR 3152, Patent Eligibility and Restoration Act (PERA) S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) HR 3160, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL)

Client expense: $720,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Discussions regarding automotive right to repair efforts (H.R.1566 - Right to Equitable and Professional Auto Industry Repair Act; entire bill) Discussions regarding several patent bills, including: Patent Eligibility Restoration Act (PERA; S.1546 and H.R. 3152) and Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL; S. 1553; HR 3160) (entire bills) Discussions regarding right to repair efforts in HR 8800 (Sec 861) and S 4784 (Sec 804), the National Defense Authorization Act for FY 2027

Client expense: $1,142,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $870,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.

Client expense: Not reported · Firm income: $450,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE

Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform. H.R. 1574, RESTORE Patent Rights Act of 2025. H.R. 3152, Patent Eligibility Restoration Act of 2025. H.R. 3160, PREVAIL Act. H.R. 3269, ETHIC Act. S. 708, RESTORE Patent Rights Act of 2025. S. 1546, Patent Eligibility Restoration Act of 2025. S. 1553, PREVAIL Act. S. 2276, ETHIC Act.

Client expense: $1,820,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to intellectual property, including the NO FAKES Act (S. 1367), counterfeits, music licensing, and issues related to patent reform, International Trade Commission patent investigations, intermediary liability, and patent reform, including the RESTORE Patents Act (H.R. 1574 / S. 708), the Patent Eligibility Restoration (PERA) Act (H.R. 3152 / S. 1546), and the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R. 3160 / S. 1553).

Client expense: $4,360,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

Met with Senators, Representatives, and legislative staff to discuss university intellectual property and technology transfer operations, and to encourage support for the PREVAIL (HR 3160, S.1553), PERA (HR 3512, S.1546), and RESTORE (HR 1578, S.704) Acts. Met with Senators, Representatives, and legislative staff to encourage support for efforts to prevent agencies from indiscriminately exercising march-in rights to invalidate university patents or licenses, or to discourage the administration from claiming a portion of patent royalties.

Client expense: $360,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Client expense: $2,440,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,360,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Software copyright and related policy issues. Software patents and related policy issues. S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S. 1546, Patent Eligibility Restoration Act. S. 1367, NO FAKES Act. S. 4098, AI Ready Data Act.

Client expense: $2,690,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Copyright Office, U.S. Trade Representative (USTR)